[go: up one dir, main page]

PE20220425A1 - Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 - Google Patents

Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2

Info

Publication number
PE20220425A1
PE20220425A1 PE2021001772A PE2021001772A PE20220425A1 PE 20220425 A1 PE20220425 A1 PE 20220425A1 PE 2021001772 A PE2021001772 A PE 2021001772A PE 2021001772 A PE2021001772 A PE 2021001772A PE 20220425 A1 PE20220425 A1 PE 20220425A1
Authority
PE
Peru
Prior art keywords
thiadiazine
benzo
amino
mrgx2
inhibitors
Prior art date
Application number
PE2021001772A
Other languages
English (en)
Inventor
Simone Bigi
Allison L Chambers
Tony Gibson
Jason Pickens
Steve Swann
Angie Vassar
Feng Zhou
Mitsunori Kono
Masaki Seto
Zenyu Shiokawa
Original Assignee
Solent Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solent Therapeutics Llc filed Critical Solent Therapeutics Llc
Publication of PE20220425A1 publication Critical patent/PE20220425A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta referido a compuestos derivados de 1,1-dioxido de 3-amino-5-metil-4H-benzo[e][1,2,4] tiadiazina de Formula I, en donde: L es un enlace o alcanodiilo de C1-4; R1 es alquilo, grupo ciclico, cualquiera de ellos opcionalmente sustituido; R2 es alquilo, grupo ciclico, cualquiera de ellos opcionalmente sustituido; R3, R4 y R5 son H, halo, CN, alquilo. Entre los compuestos preferidos tenemos los siguientes: 1,1-dioxido de 5-(2-cloro-3-fluorofenil)-3-(metilamino)-4H-benzo[e][1,2,4] tiadiazina; 1,1-dioxido de 5-(2-cloro-3-fluorofenil)-3-((2-metoxietil)amino)-4H-benzo[e][1,2,4] tiadiazina; entre otros. Estos compuestos son inhibidores de gen X2 relacionado con Mas (MRGX2) y se emplean en el tratamiento de enfermedades, trastornos o afecciones asociadas con MRGX, incluyendo dermatitis atopica, urticaria cronica y asma, entre otras
PE2021001772A 2019-04-29 2020-04-28 Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 PE20220425A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962840344P 2019-04-29 2019-04-29
PCT/US2020/030305 WO2020223255A1 (en) 2019-04-29 2020-04-28 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2

Publications (1)

Publication Number Publication Date
PE20220425A1 true PE20220425A1 (es) 2022-03-29

Family

ID=70779887

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001772A PE20220425A1 (es) 2019-04-29 2020-04-28 Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2

Country Status (21)

Country Link
US (2) US12247015B2 (es)
EP (1) EP3962901A1 (es)
JP (1) JP7574215B2 (es)
CN (2) CN120535477A (es)
AR (1) AR119728A1 (es)
AU (1) AU2020266529B2 (es)
BR (1) BR112021021508A2 (es)
CL (1) CL2021002805A1 (es)
CO (1) CO2021014155A2 (es)
CR (1) CR20210544A (es)
DO (1) DOP2021000223A (es)
EC (1) ECSP21080966A (es)
IL (1) IL287521B2 (es)
JO (1) JOP20210275A1 (es)
MA (1) MA55804A (es)
MX (1) MX2021013135A (es)
PE (1) PE20220425A1 (es)
PH (1) PH12021552760A1 (es)
SG (1) SG11202111717XA (es)
TW (1) TWI846868B (es)
WO (1) WO2020223255A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス，エルエルシー ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
WO2022152852A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2022152853A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2024183806A1 (en) * 2023-03-08 2024-09-12 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025037034A1 (en) * 2023-08-17 2025-02-20 Sanofi Thienothiadiazines, their preparation and their therapeutic application
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
TW202517273A (zh) * 2023-10-06 2025-05-01 美商伊賽恩特製藥公司 Ｍｒｇｐｒｘ２調節劑及相關治療方法
CN120230034A (zh) * 2023-12-29 2025-07-01 深圳阿尔法分子科技有限责任公司 喹诺酮类化合物及其用途
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
WO2026009854A1 (ja) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757999A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Substituierte aminoalkylenamino- 1.2.4-benzothiadiazine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0105732A3 (en) 1982-10-01 1985-09-04 Beecham Group Plc Histamine h2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series
EP0386931A1 (en) 1989-03-04 1990-09-12 Konica Corporation A novel cyan coupler
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6242443B1 (en) 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999032467A1 (en) 1997-12-19 1999-07-01 Novo Nordisk A/S 1,2,4-benzothiadiazine derivatives, their preparation and use
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
CA2450236A1 (en) 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
EP1340979A3 (en) 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
AU2003231359B2 (en) 2002-04-16 2009-04-30 Teijin Limited Piperidine derivatives having CCR3 antagonism
KR20040104596A (ko) 2002-04-25 2004-12-10 데이진 가부시키가이샤 Ｃｃｒ３ 길항 작용을 갖는 ４,４-２치환 피페리딘 유도체
US20050196757A1 (en) 2002-06-21 2005-09-08 Mark Zylka Identification of a receptor controlling migration and metastasis of skin cancer cells
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
JPWO2005028667A1 (ja) 2003-09-19 2006-11-30 独立行政法人理化学研究所 ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法
BRPI0506909A (pt) 2004-01-16 2007-05-29 Hoffmann La Roche derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central
EP1794589A4 (en) 2004-09-15 2010-03-17 Protometrix Inc PROTEIN ARRAYS AND METHOD OF USE THEREOF
EP1820360B1 (en) 2004-12-08 2013-02-27 Electronics and Telecommunications Research Institute Method of controlling base stations to suppress inter-cell interference
WO2006089286A2 (en) * 2005-02-18 2006-08-24 Acadia Pharmaceuticals Inc. Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor compounds useful for the treatment and prevention of pain and screening methods therefor
CA2604333A1 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
EP1876239A4 (en) 2005-04-28 2008-11-05 Takeda Pharmaceutical DEGRANULATIONSHEMMER
EP1893627A4 (en) 2005-05-27 2009-11-11 Sentigen Biosciences Inc MULTIPLEXARRAY SUITABLE FOR THE INVESTIGATION OF PROTEIN-PROTEIN INTERACTIONS
AU2006308991A1 (en) 2005-10-31 2007-05-10 University Of Rochester Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage
JP2009060787A (ja) 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
JP2010505897A (ja) 2006-10-11 2010-02-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ インフルエンザターゲット
US20080249081A1 (en) * 2006-10-24 2008-10-09 Roger Olsson Compounds for the treatment of pain and screening methods therefor
WO2008061209A2 (en) 2006-11-15 2008-05-22 Omeros Corporation G protein coupled receptors and uses thereof
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
EP2067861A1 (en) 2007-12-05 2009-06-10 Koninklijke Nederlandse Akademie van Wetenschappen Animals of the rattus genus wherein msh6 expression is functionally decreased and methods for the generation of specific mutants therefrom
JP2012167017A (ja) 2009-06-15 2012-09-06 National Cerebral & Cardiovascular Center ペプチドおよびその用途
CA2772929A1 (en) 2009-09-03 2011-03-11 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
IT1402905B1 (it) * 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
JP5932279B2 (ja) 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
ES2659184T3 (es) 2013-06-18 2018-03-14 Bayer Pharma Aktiengesellschaft Moduladores del receptor MRG
EP3099304B1 (en) 2014-01-31 2024-07-17 Mayo Foundation for Medical Education and Research Chroman derivatives and their use in the treatment of glaucoma
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
US10426815B2 (en) 2015-01-20 2019-10-01 The General Hospital Corporation Prevention and treatment of itch with an MRGPR antagonist
EP3383493B1 (en) 2015-12-04 2021-02-17 Merck Sharp & Dohme Corp. Carbocyclic fused iminothiadiazine dioxides as bace inhibitors, compositions, and their use
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2018185266A1 (en) 2017-04-06 2018-10-11 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma.
WO2018213934A1 (en) 2017-05-26 2018-11-29 The Governors Of The University Of Alberta Self-assembling peptide for activating human mast cells
FI3814348T3 (fi) 2018-06-27 2023-09-22 Bristol Myers Squibb Co Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
EP3597653A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Cyclic inhibitors of hepatitis b virus
JP7574215B2 (ja) 2019-04-29 2024-10-28 ソレント セラピューティクス，エルエルシー ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体

Also Published As

Publication number Publication date
ECSP21080966A (es) 2022-01-31
MA55804A (fr) 2022-04-06
IL287521B1 (en) 2025-09-01
US20220119361A1 (en) 2022-04-21
IL287521A (en) 2021-12-01
CO2021014155A2 (es) 2021-10-29
MX2021013135A (es) 2021-11-25
TW202106669A (zh) 2021-02-16
EP3962901A1 (en) 2022-03-09
KR20220012244A (ko) 2022-02-03
AR119728A1 (es) 2022-01-05
US20250289792A1 (en) 2025-09-18
PH12021552760A1 (en) 2022-08-15
WO2020223255A1 (en) 2020-11-05
DOP2021000223A (es) 2022-01-16
TWI846868B (zh) 2024-07-01
CN114072393A (zh) 2022-02-18
IL287521B2 (en) 2026-01-01
JP7574215B2 (ja) 2024-10-28
CN120535477A (zh) 2025-08-26
AU2020266529A1 (en) 2021-12-16
CA3137584A1 (en) 2020-11-05
JP2022535672A (ja) 2022-08-10
CR20210544A (es) 2022-03-30
US12247015B2 (en) 2025-03-11
CN114072393B (zh) 2025-05-27
SG11202111717XA (en) 2021-11-29
BR112021021508A2 (pt) 2022-03-22
JOP20210275A1 (ar) 2023-01-30
AU2020266529B2 (en) 2026-01-29
CL2021002805A1 (es) 2022-07-22

Similar Documents

Publication Publication Date Title
PE20220425A1 (es) Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
CR20200416A (es) Nuevos compuestos heterocíclicos
PH12022550339A1 (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
PE20200758A1 (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
EA202190196A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
DOP2014000097A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR060516A1 (es) Dihidrotienopirimidinas utilizables en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de pde4 y composiciones farmaceuticas que las contienen.
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW200505903A (en) CGRP receptor antagonists
PE20200388A1 (es) Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock
EP1796678A4 (en) Carboxamide-spirolactam CGRP Receptor Antagonists
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
DOP2006000210A (es) Compuestos de pirimidina amida como inhibidores de pgds
ATE466860T1 (de) Cgrp-rezeptorantagonisten
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20191784A1 (es) Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos
EP3906241A4 (en) Inhibitors of cgas activity as therapeutic agents
MX2010002295A (es) Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
AR076507A1 (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
MX2023002224A (es) Compuestos heterociclicos.
NI200500174A (es) Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias
PE20170295A1 (es) Compuestos de imidazopiridazina
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
MX2022001933A (es) Inhibidores de enzimas.